CriticalAntiretroviral, HIV protease inhibitor×Antiepileptic, hydantoin derivative (sodium channel blocker)
Updated · Methodology
Mechanism
Phenytoin is a strong inducer of the liver enzymes that metabolise drugs and can lower the levels of drugs cleared by these enzymes (phenytoin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The liver breaks down atazanavir through the enzyme CYP3A4, and the atazanavir documents class phenytoin as a strong inducer of this enzyme. Atazanavir levels may fall, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (atazanavir SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). Atazanavir boosted with cobicistat is even more sensitive to this induction (atazanavir/cobicistat SmPC, EMA). The effect can also run the other way: ritonavir in an atazanavir regimen can lower phenytoin levels by inducing CYP2C9 and CYP2C19, the enzymes that clear phenytoin (atazanavir SmPC, EMA, and phenytoin SmPC, AEMPS).
Symptoms
The combination itself usually causes no symptoms: atazanavir loses its effect, the human immunodeficiency virus (HIV) viral load rises, and the virus may become resistant to treatment (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and atazanavir label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. Ritonavir in an atazanavir regimen can lower phenytoin levels (atazanavir SmPC, EMA), and seizures may become more frequent when anticonvulsant levels fall. Stopping phenytoin abruptly can also make seizures more frequent, up to status epilepticus (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. The atazanavir documents name phenytoin among the strong CYP3A4 inducers that are contraindicated with atazanavir, both with and without ritonavir (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). The phenytoin SmPC does not name atazanavir, but it lists ritonavir among the drugs that can lower phenytoin levels (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For a person taking atazanavir, choose seizure treatment without phenytoin, carbamazepine or phenobarbital (atazanavir SmPC, EMA, and FDA label). No document gives an interval between stopping phenytoin and starting atazanavir. Do not stop phenytoin abruptly: make any dose reduction, withdrawal or switch gradually (phenytoin SmPC, AEMPS). The interaction table of the same atazanavir SmPC still contains a softer entry: it advises caution with phenytoin in the ritonavir-boosted regimen and does not recommend the combination without ritonavir. The contraindications section of this SmPC is stricter (atazanavir SmPC, EMA). If the two drugs have nevertheless been taken together, monitor the virological response closely. With a ritonavir-boosted regimen, the phenytoin dose may need adjusting (atazanavir SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fenitoína (nº registro 45695), secciones 4.3 y 4.5 (2024)– AEMPS, CIMA, Epanutin 100 mg cápsulas duras, nº registro 45695, revisión 01/2024, secciones 4.3 y 4.5
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5